Buying cheap imported drugs is a rotten deal for patients


By Robert Blancato



Presidential front-runner Donald Trump just unveiled a proposal that would authorize Americans to buy prescription drugs imported from countries like Canada. The measure sounds appealing — who wouldn’t want cheaper medicines from safe pharmacies in our northern neighbor?

Unfortunately, there’s a reason this proposal sounds too good to be true: it is.

While seemingly sensible, drug importation is a terrible idea that will put Americans at risk of harm from impure, unsafe, and counterfeit copies of prescription drugs. If he actually follows through on the proposal, Trump will be showcasing the art of the bad deal … for American patients.

He talks about how he wants to “remove barriers to entry into free markets,” including “allowing consumers access to imported, safe and dependable drugs from overseas.”

What he doesn’t say is that the United States has a safety regimen that is second to none and that depends on its being essentially a closed system. The FDA goes to tremendous lengths to ensure the safety and effectiveness of drugs sold here, including a requirement that they be manufactured only at plants that register with the agency, maintain strict manufacturing safeguards, and undergo regular inspections.

Breaking open this closed system invites abuse and increases risks because there would be no good way for consumers “to know whether drugs sold outside the U.S. meet FDA standards,” according to one agency document.

Backers of allowing drug imports say that those sold in Canada and other industrial countries are often the same product, but because of price controls imposed in those countries, they can be bought for far less than in the United States.

But as the FDA put it, supposedly ‘Canadian’ drugs “may be coming from some other country and simply passing through Canada.” In fact, one FDA operation found that 87 percent of drugs promoted as being of Canadian origin actually came from 27 different countries around the world. Many of those countries have abysmal quality controls. And Canadian officials don’t inspect drugs that are shipped into Canada and then sold internationally.

Even with all the current restrictions on drug imports, the FDA already faces a serious problem with counterfeiters and scam artists who sell drugs online. Policing such sales would become exponentially more difficult if the government starts telling consumers that it’s ok to buy drugs from abroad.

Those who support drug importation no doubt sincerely want to help patients. How will they feel when patients with treatable cancers start dying because they received counterfeit chemotherapy drugs? Or when patients have severe, even deadly, reactions from shoddily manufactured or improperly labeled treatments?

Drug importation will particularly harm poor seniors — precisely because their tight, fixed-income budgets will pressure them to turn to cheaper but potentially dangerous foreign imports.

Blocking drugs imported from other countries isn’t about free markets or competition. Most drugs sold in the U.S. already compete against generic versions, or other drugs designed to treat the same illness. And for all the hoopla about a few high-priced breakthrough drugs, pharmaceuticals account for less than 10 percent of national health spending.

Whatever limited, short-term savings might be gained from importing cheaper drugs would be vastly outweighed by the harm from breaking down the world’s best system for ensuring the safety and effectiveness of prescriptions drugs sold in America.

Robert Blancato is the executive director of the National Association of Nutrition and Aging Services Programs.

Getting too much email from Katie Behrman <[email protected]>? You can unsubscribe

By Robert Blancato

comments powered by Disqus